Medicamen Biotech signs contract for CDMO with XGX pharma

03 Apr 2025 Evaluate

Medicamen Biotech has signed a contract for CDMO with XGX pharma, European company where Medicamen will develop 6 products and will do manufacturing of these products for European company. XGX will hold MA (Market authorisation).

Earlier, the company had entered into an understanding with a prominent South African business conglomerate for registering and marketing its products in the region. South Africa represents a $4 billion pharmaceutical market and is categorized as a regulated market.

Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.

Medicamen Biotech Share Price

390.20 -9.80 (-2.45%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×